Unit 2.06/31 Lexington Drive, BELLA VISTA , NSW 2153 Ph: 1300 995 098 • www.cambium.bio • ABN 13 127 035 358 ASX Announcement 27 August 2026 Resignation/Appointment of Company Secretary and Communication Person Sydney, Australia; 27 ...
Change in Company Secretary and Communication Person
Filed with ASX · · 1 page · English
Release
Earlier from Cambium Bio
- Updated Securities Trading Policy
- Quarterly Activities/Appendix 4C Cash Flow Report
- Cambium Bio Raises A$1.0 Million via Placement
- FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
- Half Year Report and Accounts
Later from Cambium Bio
- FY26 Appendix 4G and Corporate Governance Statement
- FY26 Appendix 4E and Annual Report
- Proposed issue of securities - CMB
- Notification regarding unquoted securities - CMB
- Update - Proposed issue of securities - CMB
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio